#ESMO26

The drugs we’ve been enthusiastically discussing for the past three days:

Divarasib, Ivonescimab, Sonesitatug vedotin, Intismeran autogene, Tarlatamab, Zanidatamab, Izalontamab brengitecan, Gedatolisib, Giredestrant, Rilvegostomig, Torvutatug samrotecan, Savolitinib.........

OS, PFS, HR, new standards of care, changing treatment algorithms...

Then, for a moment, I returned to reality.

I can’t even offer a single one of these drugs to my patients!!!

Anyway, tomorrow we’ll be back to discussing which drug is going to change our clinical practice🤦‍♂️